MAPT and Alzheimer disease: Reports on multi-study validation of data-driven disease progression in human AD patients52,53 predict that cohorts of familial AD and APOE-ε4-positive subjects exhibit cerebrospinal fluid biomarkers in a distinct sequence: amyloid-β1–42, phosphorylated tau, and then total tau.